Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Clarity Pharmaceuticals has dosed the first two participants in its Co-PSMA trial, testing its innovative diagnostic product Cu-64 SAR-bisPSMA against the standard Ga-68 PSMA-11 for detecting prostate cancer recurrence. Initial results show promising safety and potential for higher detection rates, which could revolutionize prostate cancer diagnostics. This trial, led by Prof Louise Emmett at St Vincent’s Hospital in Sydney, highlights the growing demand for improved imaging techniques in prostate cancer care.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.